Mankind Pharma Enters into Exclusive In-Licensing Agreement for Insulin Degludec and Insulin Degludec + Aspart Combination for India

·21 Aug
Share:PostShare

Mankind Pharma Limited, one of India’s leading pharmaceutical companies, has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, for the commercialisation of two insulin analogues, Insulin Degludec and Insulin Degludec + Aspart Combination, in India. The partnership marks another significant step in Mankind Pharma’s strategy to strengthen its [...] The post Mankind Pharma Enters into Exclusive In-Licensing Agreement for Insulin Degludec and Insulin Degludec + Aspart Combination for India appeared first on FM Live .

F

Fm Live

Original source

Read full story

mankind pharma

Check live status on DownRightNow

Check status →

Related Stories

Health3h ago

Recover Like Josh Allen

The quarterback knows that recuperation is as important as your training regime. Here’s how he does it.

MMen's Health

Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.

Read Disclaimer